UBS Group’s Coeptis Therapeutics Warrants COEPW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-23,227
| Closed | -$279 | – | 10510 |
|
|
2026
Q1 | $279 | Buy |
23,227
+19,600
| +540% | +$235 | ﹤0.01% | 9983 |
|
|
2025
Q4 | $40 | Buy |
+3,627
| New | +$63 | ﹤0.01% | 10295 |
|
|
2025
Q1 | – | Sell |
-678
| Closed | -$15 | – | 10280 |
|
|
2024
Q4 | $15 | Buy |
678
+634
| +1,441% | +$15 | ﹤0.01% | 9789 |
|
|
2024
Q3 | $1 | Sell |
44
-4,943
| -99% | -$99 | ﹤0.01% | 9422 |
|
|
2024
Q2 | $75 | Buy |
4,987
+4,900
| +5,632% | +$123 | ﹤0.01% | 9197 |
|
|
2024
Q1 | $2 | Buy |
+87
| New | +$4 | ﹤0.01% | 9181 |
|
|
2023
Q4 | – | Sell |
-100
| Closed | -$2 | – | 9372 |
|
|
2023
Q3 | $2 | Buy |
+100
| New | +$4 | ﹤0.01% | 9345 |
|
|
2022
Q4 | – | Sell |
-13,105
| Closed | – | – | 10770 |
|
|
2022
Q3 | $0 | Buy |
13,105
+2,800
| +27% | +$134 | ﹤0.01% | 10407 |
|
|
2022
Q2 | $0 | Buy |
+10,305
| New | +$774 | ﹤0.01% | 10386 |
|
|
2021
Q4 | – | Sell |
-596
| Closed | – | – | 10302 |
|
|
2021
Q3 | $0 | Sell |
596
-6,883
| -92% | -$2.62K | ﹤0.01% | 9601 |
|
|
2021
Q2 | $4K | Buy |
7,479
+559
| +8% | +$284 | ﹤0.01% | 8656 |
|
|
2021
Q1 | $3K | Buy |
6,920
+6,588
| +1,984% | +$6.18K | ﹤0.01% | 8507 |
|
|
2020
Q4 | $0 | Buy |
+332
| New | +$306 | ﹤0.01% | 8425 |
|
Other funds holding COEPW
UBS Group's COEPW Position: Q2 2026 in Review
UBS Group sold out of Coeptis Therapeutics Warrants (COEPW) in Q2 2026, closing a stake of 23,227 shares — an estimated $279 sold.
UBS Group first reported a position in COEPW in Q4 2020 and held it in 13 quarters. The position peaked at $4K in Q2 2021. 3 funds tracked by Wall St. Rank hold COEPW as of Q2 2026.
- UBS Group reported no remaining Coeptis Therapeutics Warrants position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 23,227 Coeptis Therapeutics Warrants shares in Q2 2026, an estimated $279.
- UBS Group first reported a position in Coeptis Therapeutics Warrants in Q4 2020 and held it in 13 quarters.
- UBS Group's Coeptis Therapeutics Warrants position peaked at $4K in Q2 2021.
- 3 funds tracked by Wall St. Rank held Coeptis Therapeutics Warrants as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.